{"id":"evorel-conti","safety":{"commonSideEffects":[{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Skin irritation at patch site"},{"rate":null,"effect":"Vaginal bleeding/spotting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The patch releases estradiol (a natural estrogen) and norethisterone (a synthetic progestin) through the skin in a continuous manner, bypassing first-pass hepatic metabolism. This maintains stable hormone levels to alleviate vasomotor symptoms (hot flushes, night sweats) and other menopausal symptoms while the progestin component protects the endometrium in women with an intact uterus.","oneSentence":"EVOREL CONTI is a transdermal patch that delivers continuous estradiol and norethisterone to provide hormone replacement therapy for menopausal symptoms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:36:03.977Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Menopausal vasomotor symptoms (hot flushes, night sweats)"},{"name":"Menopausal urogenital symptoms"},{"name":"Osteoporosis prevention in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT02264743","phase":"PHASE4","title":"Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy","status":"UNKNOWN","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","startDate":"2013-11","conditions":"Venous Thrombosis, Insulin Resistance","enrollment":60},{"nctId":"NCT01300676","phase":"PHASE2, PHASE3","title":"The Effects of Tualang Honey on Postmenopausal Women","status":"COMPLETED","sponsor":"Universiti Sains Malaysia","startDate":"2009-03","conditions":"Postmenopausal Syndrome","enrollment":79},{"nctId":"NCT00623116","phase":"NA","title":"A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland","status":"UNKNOWN","sponsor":"Hospital for Children and Adolescents, Finland","startDate":"2007-12","conditions":"Kallmann Syndrome","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Evorel Conti transdermal patch 25 mcg transdermal dose"],"phase":"marketed","status":"active","brandName":"EVOREL® CONTI","genericName":"EVOREL® CONTI","companyName":"Royal Brompton & Harefield NHS Foundation Trust","companyId":"royal-brompton-harefield-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EVOREL CONTI is a transdermal patch that delivers continuous estradiol and norethisterone to provide hormone replacement therapy for menopausal symptoms. Used for Menopausal vasomotor symptoms (hot flushes, night sweats), Menopausal urogenital symptoms, Osteoporosis prevention in postmenopausal women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}